Skip to main content
. 2020 Jan 27;2020(1):CD010061. doi: 10.1002/14651858.CD010061.pub4

ACTRN12613000289718.

Trial name or title Paracetamol for patent ductus arteriosus treatment: comparison between oral and intravenous administration
Methods Randomised controlled trial. Blinded (masking used). Researchers assessing ductal closure by ECHO will be unaware for study aims and group assignment
Participants Neonates with PMA < 32 weeks and birth weight < 1500 g and with ECHO evidence of PDA and contraindication to or failure of conventional medical therapy with COX inhibitors (ibuprofen or indomethacin)
Age 1 to 5 days
Interventions Intravenous paracetamol at a loading dose of 20 mg/kg, followed by 7.5 mg/kg every 6 h for 7 days. If ductal closure evaluated by colour‐Doppler ultrasound occurs before the 7th day of treatment, therapy will be discontinued
Paracetamol at 15 mg/kg by oral route, every 6 h for 7 days. If ductal closure evaluated by colour‐Doppler ultrasound occurs before the 7th day of treatment, therapy will be discontinued
Outcomes Ductal closure, assessed by colour‐Doppler ultrasound at 7 days after allocation to the intervention
Mortality by 42 weeks' PMA
Starting date April 2013
Contact information Prof Gianluca Terrin, Department of Gynecology‐Obstetrics and Perinatal Medicine, Sapienza University of Rome, Italy. (gianluca.terrin@uniroma1.it)
Notes